human disease, higher expression of USP15 in human glioblastoma correlates with shorter life expectancy 4 .
Two conflicting in vitro studies have found opposing roles for USP15 in regulating the immune system's type I interferon responses, which protect the organism during viral infection but can have negative consequences in autoimmune conditions. Now, using a combined approached of N-ethyl-Nnitrosourea-induced genome-wide mutagenesis and whole-exome sequencing, Torre et al. identify a point mutation in Usp15 that introduces a leucine-to-arginine substitution at residue 749 (L749R) in USP15 (USP15 L749R ) and leads to the resistance of mice to experimental cerebral malaria (ECM) induced by infection with Plasmodium berghei, ANKA strain 1 . The loss-of-function substitution in the mutant protein USP15 L749R is associated with diminished stability of this protein in vitro. Heterozygous Usp15 L749R/+ mice show moderately improved survival, but homozygous T he integrated mechanisms that underlie the pathogenesis of infection and autoimmunity have revealed fundamental pathways of immunological activation and might represent novel targets for multi-indication therapies. In this issue of Nature Immunology, Torre et al. report the discovery of the deubiquitinase USP15 as a common factor that controls microbial and autoimmune neuroinflammation 1 (Fig. 1) . These results point to exciting new directions in understanding how the ubiquitin system might govern the susceptibility of an organism to neuroinflammatory diseases.
Deubiquitinating enzymes (DUBs) catalyze the removal of ubiquitin from other proteins and target molecules and thereby prevent the degradation of their targets or alter ubiquitindependent signaling in the cell. In addition to their catalytic domains, DUBs have noncatalytic domains that can confer function. Indeed, DUBs are now recognized as candidates for drug discovery due to the specificity of their regulation and action. Ubiquitin-specific proteases are the largest DUB family, with at least 56 cysteine proteases, including USP15.
Identified in 1999, USP15 is a regulator of the TGF-β (transforming growth factor-β) and BMP (bone-morphogenetic protein) signaling pathways via deubiquitination of TGF-β receptor I and receptor-activated signal transducers of the SMAD family [2] [3] [4] . Other targets of USP15 include E3 ubiquitin ligases, which catalyze the ubiquitination of proteins [5] [6] [7] ; this highlights the intricate feedback loops of the ubiquitin system. In mice, USP15 promotes carcinogenesis, both by stabilizing TGF-β receptor I (ref. 4 ) and by repressing the T cell response to cancer cells 6, 8 . Although no firm genetic link has been established between USP15 and
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The deubiquitinase USP15 acts with the ubiquitin ligase TRIM25 to activate a type I interferon response and exacerbate microbial and autoimmune neuroinflammation.
Usp15 L749R mice, similar to Usp15 -/-mice, are substantially protected against the lethality of ECM. ECM-resistant phenotypes have been described in several other mutant mice generated via N-ethyl-N-nitrosourea (for example, Themis I23N mice 9 ), but the Usp15 L749R mice are protected against both microbial neuroinflammation and autoimmune neuroinflammation. Torre et al. report that in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, Usp15 L749R mice are protected against death and have decreased expression of genes encoding inflammatory molecules, before disease onset 1 . These data generate sufficient interest to motivate future research into characterizing the role of USP15 in EAE experimental paradigms with less mortality and to study the role of USP15 not only in the 'pre-onset' of EAE but also the onset, peak and chronic phases of the disease. Future studies should also determine the contribution of USP15 to the hallmarks of EAE pathology, such as disruption of the blood-brain barrier, Figure 1 The USP15-mediated type i interferon response is a common pathway that regulates infection and autoimmune neuroinflammation. The deubiquitinating enzyme USP15 stabilizes the E3 ubiquitin ligase TRiM25 by removal of ubiquitin (Ub). USP15 expression by peripheral and CNS-resident cells is linked to the immunoregulatory functions of USP15 during acute neuroinflammation in ECM and EAE. The USP15-TRiM25 interaction controls the type i interferon response to exacerbate the lethality of microbial and autoimmune CNS diseases characterized by blood-brain-barrier dysfunction and recruitment of immune cells to the CNS.
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Type I interferon response . 1) . Bone-marrowtransplantation experiments show that the effect of USP15 is mediated by cells of the hematopoietic lineage. In the healthy CNS, ubiquitin-specific proteases are expressed by microglia in different brain regions and can act as negative regulators of microglial activation 12 . Torre et al. show increased expression of USP15, as well as of TRIM25, in activated human microglia and astrocytes after cytokine stimulation in vitro 1 . Other studies have shown USP15 to be a positive or negative regulator of interferon responses 5, 7 , which suggests the existence of distinct cell-type-specific downstream signaling pathways that might be dependent on or independent of the DUB activity of USP15. USP15 has ubiquitous expression, and the mice used in this study 1 are conventional knockout and mutant mice. Thus, future studies using conditional deletion of USP15 should address how USP15 signaling in CNS-resident cells and peripheral immune cells contributes to neuroinflammation.
The results of the current study 1 inform emerging themes in neuroimmunology for common mechanisms of immunoregulation in brain infection and autoimmunity. The risk of developing autoimmune CNS diseases, such as multiple sclerosis, is determined by a complex interaction of multiple gene variations and environmental factors, potentially including infection 13 . The extent to which the observed effects of USP15 can be generalized to viral or bacterial infections or autoimmune diseases other than multiple sclerosis will need to be explored further. Given the ubiquitous expression of USP15, it would be interesting to determine whether specificity could be achieved by targeting this pathway selectivity in the CNS. However, in the meantime, Torre et al., by a multipronged experimental paradigm 1 , have shed light on common genetic threads that might control susceptibility to both CNS infection and autoimmunity. i nterleukin 6 (IL-6) is a pleiotropic cytokine with multiple roles in the control of the immune response, metabolism and behavior in health and disease. In the context of autoimmune disease, IL-6, in combination with the cytokine TGFβ1, promotes the differentiation of helper T cells that produce IL-17 (T H 17 cells) 1,2 . IL-6 also inhibits the differentiation of Foxp3 + regulatory T cells (Treg cells) 1, 2 . In this issue of Nature Immunology, Heink et al. report that different IL-6 cellular sources and signaling mechanisms participate in the generation of pathogenic T H 17 cells and the suppression of Foxp3 + T reg cells in vivo 3 . These findings identify previously unknown molecular mechanisms used by IL-6 to control T cell responses and will probably guide new therapeutic approaches for immunomodulation.
Several cellular sources of IL-6 have been identified, including stromal cells, dendritic cells (DCs), monocytes and B cells. However, it is still unknown whether the source of IL-6 influences T cell fate during an immune response. To address this issue, Heink et al. generate a transgenic mouse strain that allows them to monitor IL-6 expression as well as its conditional deletion in various cell types 3 . Using experimental autoimmune encephalitis as a model, the authors find that IL-6 production by DCs, but not its production by other cells, drives the generation of pathogenic T H 17 cells 3 . However, sources of IL-6 other than DCs are involved in suppressing the differentiation of Foxp3 + T reg cells in vivo 3 .
